αVβ8 integrin targeting to prevent posterior capsular opacification

Mahbubul H. Shihan, …, Adam P. Faranda, Melinda K. Duncan


**Graphical abstract**

Find the latest version:

https://jci.me/145715/pdf
α_vβ_8 integrin targeting to prevent posterior capsular opacification

Mahbubul H. Shihan,1 Samuel G. Novo,1 Yan Wang,1 Dean Sheppard,2 Amha Atakilit,2 Thomas D. Arnold,3 Nicole M. Rossi,1 Adam P. Faranda,1 and Melinda K. Duncan1

1Department of Biological Sciences, University of Delaware, Newark, Delaware, USA. 2Lung Biology Center, Department of Medicine, and 3Department of Pediatrics, University of California, San Francisco, San Francisco, California, USA.

Fibrotic posterior capsular opacification (PCO), a major complication of cataract surgery, is driven by transforming growth factor-β (TGF-β). Previously, α_v integrins were found to be critical for the onset of TGF-β-mediated PCO in vivo; however, the functional heterodimer was unknown. Here, α_v integrin–conditional knockout (β_8ITG-cKO) lens epithelial cells (LCs) attenuated their fibrotic responses, while both β_1 and β_8 integrin–null LCs underwent fibrotic changes similar to WT at 5 days post cataract surgery (PCS). RNA-Seq revealed that β_8ITG-cKO LCs attenuated their upregulation of integrins and their ligands, as well as known targets of TGF-β–induced signaling, at 24 hours PCS. Treatment of β_8ITG-cKO eyes with active TGF-β1 at the time of surgery rescued the fibrotic response. Treatment of WT mice with an anti-α_vβ_8 integrin function blocking antibody at the time of surgery ameliorated both canonical TGF-β signaling and LC fibrotic response PCS, and treatment at 5 days PCS, after surgically induced fibrotic responses were established, largely reversed this fibrotic response. These data suggest that α_vβ_8 integrin is a major regulator of TGF-β activation by LCs PCS and that therapeutics targeting α_vβ_8 integrin could be effective for fibrotic PCO prevention and treatment.

Introduction

Cataracts, a major cause of blindness (1), are treated by surgical removal of opaque lens cells followed by implantation of an artificial intraocular lens (IOL) (1). However, months to years later, a significant proportion of patients experience an apparent recurrence of their cataract as posterior capsular opacification (PCO) (2, 3). PCO occurs when the remnant lens epithelial cells (LCs) left behind post cataract surgery (PCS) migrate into the optical axis and transition into a mixture of myofibroblasts and aberrant lens fiber cells (3). Approximately 25% of adult human and veterinary patients, and almost 100% of pediatric patients who do not receive prophylactic posterior capsulotomy, develop clinically significant PCO within months to years PCS (4). PCO in adults is treated by neodymium:YAG (Nd:YAG) laser capsulotomy (2), although this is often unsuitable/inconvenient for pediatric and veterinary therapy (4). As Nd:YAG laser capsulotomy can also cause side effects, including macular edema and retinal detachment, PCO prevention is desirable (2, 4).

Currently, the only US FDA–approved approach to prevent PCO utilizes prosthetic IOLs, which sequester remnant LCs to the capsular bag periphery, an innovation that delays, but often does not prevent, PCO (4). Transforming growth factor–β (TGF-β) signaling mediates the epithelial-mesenchymal transition (EMT) of LCs to myofibroblasts (6). While TGF-β concentrations in the aqueous humor are high before surgery, most of this TGF-β is inactive (7). Using a mouse cataract surgery model, we previously demonstrated that canonical TGF-β signaling is not easily detected in LCs until 48 hours PCS, with robust activation initiating at 3 days PCS (8). However, the mechanisms by which cataract surgery results in TGF-β signaling activation are unknown.

Integrins, heterodimeric extracellular matrix (ECM) receptors consisting of 1 α and 1 β subunit, mediate cell/ECM attachment, cell migration, and force transmission (9). Integrins also cross-talk with growth factor signaling (10), including the TGF-β pathway (11, 12). Thus, integrins are potential therapeutic targets for PCO prevention and/or treatment (9). Previously, we found that α_v integrins are critical for fibrotic PCO (13) consistent with their known roles in latent TGF-β activation (14, 15). Notably, the α_v integrin subunit heterodimerizes with a variety of β integrins (16), 4 of which (β_1, β_3, β_5, and β_8) upregulate in LCs PCS with dynamics similar to α_v (13). Since each α_v integrin heterodimer binds different ligands, and is inhibited by different compounds (17), the identification of the β subunit that pairs with α_v to drive PCO is critical to both the
development of anti-PCO therapies and the investigation of operant signaling mechanisms. In this study, we demonstrate that the gene encoding the \( \beta_3 \) integrin subunit is necessary for LCs to trigger TGF-\( \beta \) signaling and fibrotic responses PCS and show that an \( \alpha_\beta \) integrin function blocking antibody ameliorates PCS TGF-\( \beta \) signaling and fibrosis, suggesting a possible therapeutic approach for PCO prevention.

Results
Neither \( \beta \) nor \( \beta_6 \) integrins are critical for LC fibrosis PCS; however, \( \beta_\alpha \) integrin protein levels upregulate in a pattern correlating with TGF-\( \beta \) signaling induction in LCS. Our prior study revealed that an \( \alpha_\beta \) integrin is critical for the fibrotic response of LCs PCS (13). As \( \alpha_\beta \) integrins are heterodimers between the \( \alpha_\beta \) integrin subunit and one of several possible \( \beta \) integrins (16), we sought to identify which \( \alpha_\beta \) integrin complex regulates the LC response to surgery. As \( \beta_\alpha \) and \( \beta_6 \) integrin levels upregulate in LCS PCS (13), and \( \alpha_\beta \) and \( \alpha_\beta \) integrins can regulate fibrosis (14, 18–20), we first characterized potential roles for \( \beta_\alpha \) and \( \beta_6 \) integrin in fibrotic PCS. \( \beta_\alpha \) and \( \beta_\alpha \) integrin–null adult lenses were transparent (not shown) and exhibited fibrotic responses, and canonical TGF-\( \beta \) signaling, at 5 days PCS similar to WT, as measured by the expression of a myofibroblast marker, \( \alpha \)-smooth muscle actin (\( \alpha \)-SMA; Figure 1, A and B; \( \beta_\alpha \) integrin–null, \( P = 0.999 \); \( \beta_\alpha \) integrin–null, \( P = 0.988 \)), and SMAD2/3 phosphorylation (Figure 1, A and C; \( \beta_\alpha \) integrin–null, \( P = 0.847 \); \( \beta_\alpha \) integrin–null, \( P = 0.513 \)). Similarly, systemic administration of either an \( \alpha_\beta \) IBA or \( \alpha_\beta \) IBA to WT mice following fiber cell removal did not alter the fibrotic response of LCS following lens injury (\( \alpha \)-SMA; Figure 1, A and B; WT \( \alpha_\beta \) IBA, \( P = 0.830 \); WT \( \alpha_\beta \) IBA, \( P = 0.958 \) (TGF-\( \beta \) signaling PCS [p-SMAD2/3]; Figure 1, A and C; WT \( \alpha_\beta \) IBA, \( P = 0.427 \); WT \( \alpha_\beta \) IBA, \( P = 0.382 \)). Overall, this suggests that neither \( \alpha_\beta \) nor \( \alpha_\beta \) integrins are essential for LC EMT PCS.

Next, the \( \beta_\alpha \) integrin subunit was investigated as \( \alpha_\beta \) integrin activates latent TGF-\( \beta \) in some circumstances (14, 15). At 0 hours PCS, remnant LCs expressed little \( \beta_\alpha \) integrin protein (Figure 2, A and B), but its levels rose between 24 and 48 hours PCS (Figure 2, A and B; \( P \leq 0.001 \)); this was robust by 3 days PCS (Figure 2, A and B; \( P \leq 0.001 \)). \( \beta_\alpha \) integrin expression was sustained through 5 days PCS (Figure 2, A and B; \( P \leq 0.001 \)) though its levels were significantly lower than 3 days PCS. In addition, both \( \alpha_\beta \) and \( \beta_\alpha \) integrin levels were similar between WT, \( \beta_\alpha \) integrin–null, and \( \beta_\alpha \) integrin–null capsular bags at 5 days PCS (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.145715DS1), suggesting that \( \alpha_\beta \) integrin upregulation PCS is not dependent on either \( \alpha_\beta \) integrin or \( \beta_\alpha \) integrin. Further, neither \( \alpha_\beta \) nor \( \beta_\alpha \) integrin protein was detected in the intact human lens, but bright \( \alpha_\beta \) and \( \beta_\alpha \) integrin staining was detected in LCs exhibiting high levels of \( \alpha \)-SMA lining a human capsular bag collected several years after cataract surgery (Figure 2, C and D), indicating that \( \alpha_\beta \) integrin upregulation in LCS PCS is conserved between humans and mice and may persist for extended times PCS.

Because \( \beta_\alpha \) subunit protein level elevation observed in LCS PCS correlates with the timing of robust TGF-\( \beta \) signaling (8), we studied the function of \( \alpha_\beta \) integrin in PCS by generating mice lacking the \( Igb8 \) gene from the lens (\( \beta_8 \) ITG-cKO) by mating mice carrying a floxed \( Igb8 \) allele (21) to mice harboring the lens-specific MLR10-Cre transgene (22) (Figure 3A). The deletion of the floxed region of \( Igb8 \) was confirmed by PCR analysis of genomic DNA isolated from adult lenses (Figure 3B) and by immunofluorescence of \( \beta_\alpha \) integrin protein in WT and \( \beta_8 \) ITG-cKO LCs at 5 days PCS (Supplemental Figure 2). Adult \( \beta_8 \) ITG-cKO lenses (2–12 months old) are transparent (Figure 3C) and have refractive properties similar to WT (Figure 3D), suggesting that \( \beta_8 \) ITG-cKO lenses (8–14 months old) were 3.34% larger in diameter than WT lenses of similar age (\( P = 0.012 \)), consistent with the phenotype of adult mouse lenses lacking the \( \alpha_\beta \) integrin gene (\( Igb8 \)) (13), suggesting that \( \alpha_\beta \) integrin may regulate lens growth.

Lenses lacking \( Igb8 \) attenuate cell proliferation and fibrotic responses PCS while retaining their epithelial characteristics and ability to regenerate lens fiber cells. The response of \( \beta_8 \) ITG-cKO LCs to lens fiber cell removal was tested by following the expression of the myofibroblast marker, \( \alpha \)-SMA, and the fibrillar matrix proteins tenasin C and fibronectin (23) PCS (Figure 4, A–D). As expected, little to no \( \alpha \)-SMA, tenasin C, or fibronectin protein were seen in or around remnant LCs associated with either WT or \( \beta_8 \) ITG-cKO capsular bags at 0 hours PCS. By 48 hours PCS, both WT and \( \beta_8 \) ITG-cKO LCs upregulated all 3 proteins; however, \( \beta_8 \) ITG-cKO LCs attenuated their upregulation of tenasin C (Figure 4, A and C; \( P = 0.005 \)) and fibronectin (Figure 4, A and D; \( P = 0.022 \)) protein compared with WT while \( \alpha \)-SMA levels remained similar (Figure 4, A and B; \( P = 0.446 \)). WT LCs further upregulated all 3 fibrotic proteins (Figure 4, A–D) (\( \alpha \)-SMA, \( P \leq 0.001 \); tenasin C, \( P = 0.002 \); fibronectin, \( P = 0.003 \)) 5 days PCS. In contrast, \( \beta_8 \) ITG-cKO LCs still expressed less of these proteins 5 days PCS compared with WT (Figure 4, A and B–D) (\( \alpha \)-SMA, \( P = 0.001 \); tenasin C, \( P \leq 0.001 \); fibronectin, \( P = 0.005 \)), suggesting \( Igb8 \) deletion from the lens inhibits the fibrotic response of remnant LCs PCS.
We next investigated the expression of an epithelial cell marker, E cadherin, to determine if β8ITG-cKO LCs retain their epithelial character PCS. As expected, both WT and β8ITG-cKO LCs expressed E cadherin protein at 0 hours PCS (Figure 4, A and E). However, by 48 hours PCS, E cadherin protein levels were downregulated in WT LCs (Figure 4, A and E; \( P \leq 0.001 \)), and this downregulation was sustained through 5 days PCS (Figure 4, A and E; \( P \leq 0.001 \)). In contrast, E cadherin levels were unchanged in β8ITG-cKO 48 hours (Figure 4, A and E; \( P = 0.651 \)) and 5 days PCS (Figure 4, A and E; \( P = 0.390 \)), suggesting that Itgb8-null LCs preserve their epithelial characteristics PCS.

Because the cells associated with β8ITG-cKO capsular bags at 5 days PCS are no longer in a monolayer along the capsule, the expression of aquaporin 0, a fiber cell preferred membrane protein, was investigated;
some LCs differentiate into structurally aberrant lens fiber cells during PCO pathogenesis, contributing to “pearl-like” PCO when in the visual axis and Soemmering’s ring when restricted to the capsular bag periphery (3). Remnant LCs from WT and β8ITG-cKO mice expressed little aquaporin 0 (Figure 4, A and F) immediately PCS. By 48 hours PCS, WT and β8ITG-cKO capsular bags were associated with some aquaporin 0–expressing cells and robustly so by 5 days PCS (Figure 4, A and F; WT $P \leq 0.001$; β8ITG-cKO $P = 0.003$), indicating that β8ITG-cKO LCs can differentiate into lens fiber-like cells PCS to a similar extent as WT. Notably, fewer cells were associated with β8ITG-cKO capsular bags than WT at 5 days PCS ($P \leq 0.001$) (Figure 4G). Because apoptosis was not detected in the capsular bags of either WT or β8ITG-cKO mice at any time PCS (data not shown), LC proliferation was investigated by following the expression of Ki67, a marker of all cell cycle stages except G0 (24). At 0 hours PCS, few to no remnant LCs were proliferating (Figure 4, H and I) in WT or β8 integrin protein levels are upregulated in LCs PCS. (A) β8 integrin protein (red) levels are low in remnant LCs immediately PCS but upregulate in α-SMA–positive (green) remnant LCs and are robust by 3 days PCS. Scale bar (A): 36 μm. (B) Quantitation of the data from A with the mean fluorescence intensity (MFI) values measured in lens capsule–associated cells ± SEM is presented for 1 representative experiment of 2 independent experiments, with similar results; (*$P \leq 0.05$; **$P \leq 0.01$; ***$P \leq 0.001$, n = 3); 1-way ANOVA with Tukey’s post hoc test. (C and D) Unoperated human LCs obtained from a cadaver eye exhibit modest α-SMA staining consistent with its previously reported presence in naive LCs (75), though they have little to no α integrin (red in C) or β8 integrin protein (red in D). In contrast, islands of LCs associated with a human lens capsule/IOL complex exhibit bright immunostaining of α integrin (C), β8 integrin (D), and the myofibroblast marker α-SMA (green). (Scale bars for C and D: 72 μm.) Graph colors: (B) red (WT 0 hours), green (WT 24 hours), blue (WT 48 hours), orange (WT 3 days), purple (WT 5 days). C, lens capsule; LC, remnant lens cells; a, anterior; p, posterior; e, epithelial cells; f, fiber cells; PCS, post cataract surgery; WT, wild-type; β8ITG-cKO, β8 integrin conditional knockout. RNA-Seq reveals genes associated with fibrosis and inflammation are differentially expressed in β8ITG-cKO LCs PCS. Because phenotypic differences between WT and β8ITG-cKO LCs manifest by 48 hours PCS, we performed RNA-Seq on WT and β8ITG-cKO LCs at 24 hours PCS to gain insight into this phenotype’s proximal cause. This revealed 2312 genes differentially expressed in WT LCs at 24 hours PCS compared with 0 hours PCS (1273 genes upregulated, 1039 genes downregulated under criteria for biologically significant differences; ref.
As we previously reported (8, 26), the upregulated genes included those that participate in tissue inflammation (Supplemental Table 4) and fibrosis (Supplemental Table 5), while many genes important for lens structure and function were downregulated (Supplemental Table 6).

Comparison between WT and β8ITG-cKO LCs at 24 hours PCS revealed that 828 genes were differentially expressed under the biological significance criteria (25) (Supplemental Figure 3). Of these, 97 were upregulated in WT LCs by 24 hours PCS but not in β8ITG-cKO LCs (Supplemental Table 7). Consistent with β8ITG-cKO LCs’ muted fibrotic response PCS, several of these were associated with fibrotic disease while others regulate inflammation (Supplemental Table 8).

β8ITG-cKO LCs fail to upregulate known TGF-β-responsive genes PCS, while attenuating their activation of TGF-β signaling, and this is rescued by adding active TGF-β1 (27) while genes known either to regulate (gremlin-1 [Grem1], Thbs1, Fln1, Itga5) (23, 28–30), or to be regulated by TGF-β signaling (Acta2, Tnc) (23, 31), were differentially expressed in β8ITG-cKO LCs 24 hours PCS (Supplemental Table 8 and Figure 5A). Comparison with TGF-β–regulated genes in cultured cells (32) revealed 60 genes upregulated by TGF-β treatment exhibited attenuated upregulation in β8ITG-cKO LCs (Supplemental Table 9) but 47 genes downregulated by TGF-β treatment expressed at higher levels in β8ITG-cKO LCs at 24 hours PCS (Supplemental Table 10), suggesting αvβ8 integrin affects TGF-β pathway activation PCS (OR 2.99, P = 6.3 × 10−4).

Thus, canonical TGF-β pathway activation PCS was determined in WT and β8ITG-cKO LCs by assaying the downstream effector of TGF-β signaling, p-SMAD2/3 (33) (Figure 5, B and C). As we previously reported (8), elevated p-SMAD2/3 levels were first detectable in WT LCs 48 hours PCS (Figure 5, B and C; P = 0.013) while this induction was attenuated in β8ITG-cKO LCs (Figure 5, B and C; P = 0.042). Further, while WT LCs further enhanced this signaling by 5 days PCS (Figure 5, B and C; P < 0.001), p-SMAD2/3 levels remained low in β8ITG-cKO LCs (Figure 5, B and C; P < 0.001), suggesting that TGF-β signaling PCS depends on the upregulation of β8 integrin expression.

Because active TGF-β induces LC conversion to myofibroblasts (6), and β8ITG-cKO LCs exhibit reduced TGF-β signaling PCS, we tested whether exogenous active TGF-β could rescue these defects (Figure 5, D–I). As active TGF-β1 treatment of β8ITG-cKO capsular bags caused robust induction of SMAD2/3 phosphorylation (Figure 5, D and E; P < 0.001) and α-SMA (Figure 5, D and F; P = 0.011), tenascin C (Figure 5, D and G; P = 0.007), fibronectin (Figure 5, D and H; P = 0.012), and collagen I (Figure 5, D and I; P = 0.003) 5 days PCS, αvβ8 integrin may play a key role in activating TGF-β signaling in LCs PCS.
Blocking the interaction of TGF-β latency associated peptide with αVβ8 integrin in WT LCs phenocopies the attenuated fibrotic response and TGF-β signaling defects detected in β8ITG-cKO LCs PCS. TGF-β is secreted from cells bound to its latency associated peptide (LAP) and latent binding proteins, forming the latent TGF-β complex (14). Upon secretion, the latent TGF-β complex is tethered to the ECM by binding to matrix proteins such as fibronectin (14, 23). The release of active TGF-β1 from the latent complex can be accomplished by the interaction of the LAP with integrins such as αVβ8 (12, 14). Thus, we next tested whether αVβ8 integrin function-blocking antibody (ADWA-11), which antagonizes LAP binding to αVβ8 integrin (αVβ8-IBA), thus blocking TGF-β activation (34), can influence the fibrotic response of LCs (Figure 6, A–F).
measured by p-SMAD2/3 (Figure 6, A and B; \( P = 0.017 \)) 3 days PCS, the time when robust TGF-β signaling is first detected in LCs (8). This correlated with attenuated fibrotic response of LCs measured by \( \alpha \)-SMA (Figure 6, A and C; \( P = 0.002 \)), tenascin C (Figure 6, A and D; \( P = 0.003 \)), fibronectin (Figure 6, A and E; \( P \leq 0.001 \)), and collagen I (Figure 6, A and F; \( P = 0.019 \)) levels. As these attenuations...
were similar to that observed in β8ITG-cKO LCs (Figure 6, A–F), αVβ8-IBA likely blocks TGF-β activation and subsequent fibrotic response of LCs PCS.

We confirmed that αVβ8-IBA works at the level of TGF-β activation by coadministering active TGF-β1 (into the capsular bag) and αVβ8-IBA (systemically) to β8ITG-cKO mice at surgery (Figure 6, G–I). As expected, active TGF-β1 rescued the TGF-β activation defect in β8ITG-cKO LCs and subsequent fibrosis at 3 days PCS even in the presence of αVβ8-IBA measured by p-SMAD3 (Figure 6, G and H, P = 0.008) and α-SMA (Figure 6, G and I, P = 0.033). This confirms that αVβ8-IBA reduces LC fibrosis PCS by blocking the interaction of TGF-β LAP with αVβ8 integrin.

Next, we tested if a single treatment with αVβ8-IBA at the time of fiber removal reduces LC fibrosis later PCS (Figure 7, A–F). Thus, αVβ8-IBA was administered to WT mice at cataract surgery, and the samples were harvested 5 days PCS (when LCs exhibit sustained fibrotic responses and robust TGF-β signaling; ref. 23). αVβ8-IBA–treated WT mice exhibited attenuated TGF-β signaling and fibrotic responses measured by reduced p-SMAD3 (Figure 7, A and B; P = 0.008) and α-SMA (Figure 7, A and C; P ≤ 0.001), tenascin C (Figure 7, A and D; P = 0.003), fibronectin (Figure 7, A and E; P ≤ 0.001), and collagen I (Figure 7, A and F; P = 0.019). αVβ8-IBA–treated WT mice exhibited attenuated TGF-β signaling and fibrotic responses measured by reduced p-SMAD3 (Figure 7, A and B; P = 0.008) and α-SMA (Figure 7, A and C; P ≤ 0.001), tenascin C (Figure 7, A and D; P = 0.003), fibronectin (Figure 7, A and E; P ≤ 0.001), and collagen I (Figure 7, A and F; P = 0.019). Scale bar: 35 μm. Controls were treated with an isotype-matched antibody (anti–human αVβ3 integrin that does not cross-react with mouse αVβ3 integrin); p-SMAD3, tenascin C, fibronectin, collagen I (red); α-SMA (green); DNA detected by Draq5/DAPI (blue). All experiments had n = 3. Values are expressed as mean ± SEM presented for 1 representative experiment of 2 independent experiments, with similar results; asterisks indicate statistically significant MFI between 2 groups at an indicated time point PCS (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001); 1-way ANOVA with Tukey’s post hoc test. Graph colors: (B–F) red (WT), green (β8ITG-cKO), blue (WT [αVβ8-IBA]); (H and I) red (WT), green (β8ITG-cKO), blue (β8ITG-cKO [TGF-β]), orange (WT [αVβ8-IBA]), purple (β8ITG-cKO [TGF-β+ αVβ8-IBA]), C, lens capsule; LC, remnant lens cells; PCS, post cataract surgery.

Figure 6. Treatment of WT mice with an αVβ8-IBA prevents SMAD3 phosphorylation and fibrotic marker expression PCS. (A–F) The administration of an αVβ8-IBA to WT mice inhibited TGF-β signaling and LC fibrotic responses at 3 days PCS to an extent similar to β8ITG-cKO as measured by its effect on SMAD3 phosphorylation (A and B; P = 0.017), and the expression levels of α-SMA (A and C; P = 0.002), tenascin C (A and D; P = 0.003), fibronectin (A and E; P ≤ 0.001), and collagen I (A and F; P = 0.019). (G–I) Coadministration of an αVβ8-IBA with active TGF-β1 in β8ITG-cKO capsular bags at surgery rescues the attenuated fibrosis and TGF-β activation seen in β8ITG-cKO LCs (TGF-β+αVβ8-IBA) as measured by α-SMA (G and I, P = 0.033) and p-SMAD3 (G and H, P = 0.008) at levels similar to treatment with active TGF-β1 alone (G and I, α-SMA, P = 0.951; G and H, p-SMAD3, P = 0.351). Scale bar: 35 μm. Controls were treated with an isotype-matched antibody (anti–human αVβ3 integrin that does not cross-react with mouse αVβ3 integrin); p-SMAD3, tenascin C, fibronectin, collagen I (red); α-SMA (green); DNA detected by Draq5/DAPI (blue). All experiments had n = 3. Values are expressed as mean ± SEM presented for 1 representative experiment of 2 independent experiments, with similar results; asterisks indicate statistically significant MFI between 2 groups at an indicated time point PCS (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001); 1-way ANOVA with Tukey’s post hoc test. Graph colors: (B–F) red (WT), green (β8ITG-cKO), blue (WT [αVβ8-IBA]); (H and I) red (WT), green (β8ITG-cKO), blue (β8ITG-cKO [TGF-β]), orange (WT [αVβ8-IBA]), purple (β8ITG-cKO [TGF-β+ αVβ8-IBA]), C, lens capsule; LC, remnant lens cells; PCS, post cataract surgery.
and D; \( P = 0.008 \)), fibronectin (Figure 7, A and E; \( P = 0.025 \)), and collagen I (Figure 7, A and F; \( P = 0.016 \)) levels until at least 5 days PCS. Further, like \( \beta_8 \)ITG-cKO capsular bags, \( \alpha V \beta 8 \)-IBA–treated WT capsular bags exhibited less LC proliferation 3 days PCS (Figure 7, G–I; \( \beta_8 \)ITG-cKO, \( P = 0.031 \); \( \alpha V \beta 8 \)-IBA \( P = 0.048 \)) than controls. This supports the idea that blockade of TGF-\( \beta \) activation at the time of lens injury is sufficient to prevent the fibrotic transformation of LCs.

Finally, we investigated whether \( \alpha V \beta 8 \)-IBA could arrest or reverse fibrotic PCO once established. Lens fibers were removed from WT mice, and 5 days PCS, they were treated systemically with either a single dose of \( \alpha V \beta 8 \)-IBA, or 2 doses of \( \alpha V \beta 8 \)-IBA given at 5 and 7.5 days PCS. Samples were harvested 10 days PCS (Figure 8A). Single-dose \( \alpha V \beta 8 \)-IBA given 5 days PCS was sufficient to significantly attenuate SMAD2/3 phosphorylation 10 days PCS (Figure 8, B and C; WT vs. WT \( \alpha V \beta 8 \)-IBA-1 dose \( P = 0.007 \)) to a similar extent as \( \beta_8 \)ITG-cKO LCs (Figure 8, B and C; WT vs. \( \beta_8 \)ITG-cKO \( P = 0.009 \)). Similarly, fibrotic marker protein levels were also significantly attenuated in \( \alpha V \beta 8 \)-IBA–treated mice 10 days PCS compared with vehicle, and these attenuations were similar to those observed in \( \beta_8 \)ITG-cKO LCs (Figure 8, A and D; tenasin C WT vs. WT \( \alpha V \beta 8 \)-IBA-1 dose \( P = 0.002 \); WT vs. \( \beta_8 \)ITG-cKO \( P = 0.001 \)) (Figure 8, B and E; fibronectin WT vs. WT...
αβ8-IBA dose $P = 0.015$; WT vs. β8ITG-cKO $P = 0.002$) (Figure 8, B and F; collagen I WT vs. WT αβ8-IBA-1 dose $P = 0.012$; WT vs. β8ITG-cKO $P = 0.001$).

However, single-dose αβ8-IBA given 5 days PCS was insufficient to significantly attenuate α-SMA protein levels (Figure 8, B and G; WT vs. WT αβ8-IBA-1 dose $P = 0.067$). Notably, 2 doses of αβ8-IBA given 5 and 7.5 days PCS was sufficient to significantly reduce α-SMA levels (WT vs. WT αβ8-IBA-2 doses $P = 0.013$).

Figure 8. An αβ8-IBA can halt or reverse LC fibrosis PCS. (A) Dosing regimen for αβ8-IBA administration. (B and C) Treatment with αβ8-IBA starting at 5 days PCS inhibited SMA3 phosphorylation (B and C; WT vs. WT αβ8-IBA-1 dose $P = 0.007$) (B and C; WT vs. WT αβ8-IBA-2 doses $P = 0.004$), at 10 days to levels similar to β8ITG-cKO LCs (B and C). WT vs. β8ITG-cKO $P = 0.009$; β8ITG-cKO vs. WT αβ8-IBA-1 dose $P = 0.999$; β8ITG-cKO vs. WT αβ8-IBA-2 doses $P = 0.903$). Tenascin C (B and D; WT vs. WT αβ8-IBA-1 dose $P = 0.002$; WT vs. WT αβ8-IBA-2 doses $P = 0.002$), fibronectin (B and E; WT vs. WT αβ8-IBA-1 dose $P = 0.015$; WT vs. WT αβ8-IBA-2 doses $P = 0.002$) and collagen I (B and F; WT vs. WT αβ8-IBA-1 dose $P = 0.012$; WT vs. WT αβ8-IBA-2 doses $P = 0.004$) staining was reduced at 10 days PCS to levels similar to β8ITG-cKO. While αβ8-IBA-1 dose did not decrease α-SMA levels at 10 days PCS, 2 doses of αβ8-IBA were effective (B and G; WT vs. WT αβ8-IBA-2 doses $P = 0.013$). Scale bar: 35 μm. Controls were treated with an isotype-matched antibody (anti-human αβ3 integrin that does not cross-react with mouse αβ3 integrin), p-SMA3, tenascin C, fibronectin, and collagen I (red); α-SMA (green); DNA (blue). All experiments had $n = 3$. Values are expressed as mean ± SEM presented for 1 representative experiment of 2 independent experiments, with similar results; asterisks indicate statistically significant MFI between WT and/or β8ITG-cKO and/or WT (αβ8-IBA-1 dose) and/or WT (αβ8-IBA-2 doses) $^{*}P ≤ 0.05$; $^{**}P ≤ 0.01$; $^{***}P ≤ 0.001$; 1-way ANOVA with Tukey’s post hoc test. Graph colors: (C–G) red (WT), green (β8ITG-cKO), blue (WT αβ8-IBA-1 dose), purple (WT αβ8-IBA-2 doses). C, lens capsule; LC, lens cells; PCS, post cataract surgery; αβ8-IBA, αβ8 integrin blocking antibody.
days PCS did significantly decrease α-SMA protein levels 10 days PCS (Figure 8, B and G; WT vs. WT α,β1-IBA-2 doses \( P = 0.013 \)). However, α-SMA protein levels were still higher in both treatment groups (Figure 8, B and G; WT α,β1-IBA-1 dose \( P = 0.008 \)) and (Figure 8, B and G; WT α,β1-IBA-2 doses, \( P = 0.038 \)) LCs compared with β1ITG-cKO LCs 10 days PCS. This suggests α,β1-IBA therapy after LC fibrosis was established halted canonical TGF-β signaling, which substantially reduced fibrosis even in the presence of some degree of EMT.

Because 3 experimental approaches revealed that TGF-β activation by α,β1 integrin is a core mechanism of PCO development, next we characterized the regulatory relationship between α,β1 integrin–mediated TGF-β activation and 2 other PCO regulators, gremlin-1 and ECM binding integrins.

Induction of α,β1 integrin is required for LCs to upregulate gremlin-1 levels PCS, though gremlin-1 does not rescue induction of canonical TGF-β signaling and fibrotic gene expression in β1ITG-cKO LCs. Previously, we reported that gremlin-1, best known as a BMP antagonist (35), upregulates in LCs by 48 hours PCS and rescues the defects in sustained canonical TGF-β signaling observed in LCs lacking the fibronectin gene (23). Here, RNA-Seq revealed that Greml1 mRNA levels were upregulated 170-fold in WT LCs at 24 hours PCS yet attenuated 3-fold in β1ITG-cKO LCs (Supplemental Tables 5 and 8 and Figure 4A). Consistent with these data, gremlin-1 protein levels were sharply upregulated in LCs associated with WT capsular bags by 3 days PCS (Supplemental Figure 4, A and B; \( P < 0.001 \)) while this upregulation was attenuated in β1ITG-cKO (Supplemental Figure 4, A and B; \( P = 0.002 \)) and WT (α,β1-IBA) (Supplemental Figure 4, A and B; \( P < 0.001 \)) LCs. This trend was also observed 5 days PCS as gremlin-1 protein levels were significantly lower in β1ITG-cKO (Supplemental Figure 4, C and D; \( P = 0.017 \)) and WT (α,β1-IBA) (Supplemental Figure 4, C and D; \( P = 0.022 \)) LCs compared with WT, while the addition of active TGF-β1 to β1ITG-cKO eyes rescued gremlin-1 protein expression compared with β1ITG-cKO (vehicle) (Supplemental Figure 4, C and D; \( P = 0.004 \)), suggesting that α,β1 integrin expression by LCs is critical for gremlin-1 upregulation PCS.

Gremlin-1 is an agonist of the canonical TGF-β pathway (36, 37) and rescues the defect in canonical TGF-β signaling observed in PCs LCs lacking the fibronectin gene (23). However, treating β1ITG-cKO mice with recombinant gremlin-1 at cataract surgery did not rescue LC fibrosis (Supplemental Figure 5, A–F). This suggests that gremlin-1–induced LC fibrosis may require the autocrine activation of TGF-β signaling, consistent with studies in other cell types (38, 39).

Upregulation of integrin expression and signaling by LCs depends on α,β1 integrin–mediated TGF-β signaling. Crosstalk between integrins and TGF-β signaling is well documented (12). Notably, LCs elevate the protein levels of α,β1 integrin and several α, integrins in response to lens injury or TGF-β treatment (Figure 9) (9, 13, 23). Either deletion of the β1 integrin gene from LCs or treatment of capsular bags with a function blocking antibody against α,β1 integrin prevents the upregulation of α, β1, and α, integrin expression and increased p-FAK, a readout of integrin signaling PCS, at 3 and 5 days PCS (Figures 9 and 10). The addition of active TGF-β1 to β1ITG-cKO capsular bags rescued the attenuated integrin expression and p-FAK signaling detected in β1ITG-cKO LCs (Figure 10) 5 days PCS compared with vehicle-treated β1ITG-cKO LCs. Our findings indicate that α,β1 integrin is essential for upregulation of TGF-β signaling in LCs PCS, which drives subsequent upregulation of integrin expression and FAK signaling.

**Discussion**

Fibrosis-mediated organ damage and failure are among the major causes of natural death worldwide because no effective therapies prevent or treat fibrosis (40). While TGF-β signaling often drives tissue fibrosis (6, 14), this pathway is difficult to target due to its complex regulation and diverse roles in normal biology (12). Integrins regulate the TGF-β pathway via their roles in latent TGF-β activation, and ability to mediate TGF-β effects, as integrin expression is often regulated by TGF-β signaling (12, 15, 41). Thus, integrins are promising therapeutic targets for organ fibrosis, and several integrin blocking agents are undergoing clinical trials (17, 42). The α, integrins are particularly promising targets for antifibrotic therapies because blocking this class of integrins can ameliorate fibrosis in several organs (43, 44).

Previously, we reported that α, integrin gene deletion from the lens prevents EMT of LCs, potentially due to their inability to initiate TGF-β signaling PCS (13). However, the identity of the β integrin subunit participating with α, integrin was not known as multiple β subunits capable of heterodimerizing with the α, integrin subunit are upregulated by LCs PCS (13). We could not study the role of α,β1 integrin in the LC response to injury in this study despite its known roles in wound healing (45), as we previously found that the Igfb1 gene is essential for lens development and homeostasis, leading adult mice lacking β1 integrin expression in the lens to be severely microphthalmic/anophthalmic (46–48). However, the deletion of neither β1, nor β1 integrin
from the lens resulted in obvious lens defects, which made it possible to characterize their role in regulating the LC response to cataract surgery in vivo.

As previously reported, mice homozygous for β5 or β6 integrin deletions are viable (49, 50), while this investigation found that LCs from these mice underwent normal fibrotic responses PCS, indicating that neither αVβ5 nor αVβ6 integrins are critical for fibrotic PCO. While these results were initially surprising as these integrins can participate in latent TGF-β activation (18, 51), αVβ5 and αVβ6 integrins’ roles in fibrotic disease are tissue and insult specific (43, 49, 52). Thus, we investigated αVβ8 integrin as (a) its expression rapidly upregulates in mouse LCs PCS and it is found on fibrotic human LCs at extended times PCS; (b) it can regulate tissue fibrosis and inflammation via binding to the RGD sequence present in the LAP of TGF-β1 and TGF-β3 (53), which activates these latent complexes via either formation of a ternary complex with membrane-type matrix metalloproteinase 1 (27), which is upregulated in LCs PCS, or traction-mediated activation (14); and (c) TGF-β1 and TGF-β3 mRNA levels are both upregulated in LCs PCS (8, 23).

Integrin αβ8 adhesion to the LAP of latent TGF-β complexes. TGF-β activation by αβ8 integrin plays roles in development, fibrosis, inflammation, and wound closure (14, 15). Notably, itgav deletion from the lens impedes TGF-β signaling and fibrotic responses PCS (13), and here we show that deletion of itgb8 from the lens (β8ITG-cKO) phenocopies this result. As the addition of active TGF-β1 rescued the attenuated TGF-β

![Figure 9](https://doi.org/10.1172/jci.insight.145715)
signaling and fibrotic responses observed in β8ITG-cKO capsular bags PCS, this suggests that αVβ8 integrin–mediated activation of latent TGF-β is critical for the development of fibrotic PCO. This hypothesis is supported by the observation that treatment of WT mice with ADW A-11, which specifically inhibits the adhesion of LAP to αVβ8 integrin (34), potently inhibits the activation of TGF-β signaling and subsequent fibrotic responses of LCs to lens fiber cell removal.

αVβ8 integrin regulates both the EMT and LC proliferation in response to lens injury. This study explored 3 potential mechanisms by which the Itgb8 gene deletion from the lens and blocking of αVβ8 integrin interaction with LAP inhibit the upregulation of proteins expressed by myofibroblasts and TGF-β signaling PCS. As LC apoptosis was apparently absent in both WT or β8ITG-cKO LCs PCS, the very large decrease in LC proliferation at 2 days and 3 days, and cell number at 5 days, PCS in β8ITG-cKO and WT (αVβ8-IBA) in concert with the reduction of fibrotic marker mRNAs in β8ITG-cKO LCs at 24 hours PCS, and reductions in fibrotic marker protein expression later PCS, suggest that the αVβ8 integrin/TGF-β signaling axis regulates both EMT and proliferation of LCs PCS, leading to fibrotic PCO.

αVβ8 integrin crosstalk with other integrins, and their signaling, in PCO. Feedforward mechanisms between αV integrins and TGF-β signaling have been previously described (12). Upon activation by αV integrins, the TGF-β signaling

Figure 10. Upregulation of integrin expression and signaling 5 days PCS by LCs depends on αVβ8 integrin. (A–E) Compared with WT LCs, both β8ITG-cKO (A and B, αV integrin, P = 0.002; A and C, α5 integrin, P < 0.001; A and D, β1 integrin, P = 0.007; A and E, p-FAK, P < 0.001) and WT LCs treated with αVβ8-IBA (A and B, αV integrin, P = 0.006; A and C, α5 integrin, P < 0.001; A and D, β1 integrin, P = 0.008; A and E, p-FAK, P < 0.001) show attenuated levels for all 3 integrins and p-FAK at 5 days PCS. The addition of active TGF-β1 to β8ITG-cKO capsular bags rescues the attenuated integrin and p-FAK levels detected in β8ITG-cKO capsular bags (A and B, αV integrin, P = 0.010; A and C, α5 integrin, P = 0.002; A and D, β1 integrin, P = 0.004; A and E, p-FAK, P < 0.001). Scale bar: 35 μm. Control mice were treated with an isotype-matched antibody (anti-human αVβ3 integrin that does not cross-react with the mouse αVβ8 integrin): αV integrin, α5 integrin, β1 integrin and p-FAK (red), α-SMA (green), DNA detected by Draq5/DAPI (blue). All experiments had n = 3. Values are expressed as mean ± SEM presented for 1 representative experiment of 2 independent experiments, with similar results; asterisks indicate statistically significant MFI between WT and/or β8ITG-cKO and/or WT (αVβ8-IBA) at an indicated time point PCS or between 2 PCS time points. (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001); 1-way ANOVA with Tukey’s post hoc test. Graph colors: (B–E) red (WT), green (β8ITG-cKO), blue (β8ITG-cKO [TGF-β]), purple (WT [αVβ8-IBA]). C, lens capsule; LC, remnant lens cells; PCS, post cataract surgery; αVβ8-IBA, αVβ8 integrin blocking antibody.
αV integrin—induced fibrosis (12). Indeed, LCs lacking αβ8 integrin attenuate the upregulation of αv, α5, and β1 integrin expression and FAK phosphorylation PCS while treatment with active TGF-β1 reverses these defects. These findings have 2 implications: 1) targeting αβ8 integrin could suffice to prevent TGF-β activation in PCO; 2) the resulting attenuation of fibronectin fibril deposition (likely mediated by αβ8 integrin) may contribute to the long-term prevention of fibrotic PCO, as we have previously reported that fibronectin assembly is required for sustained LC fibrosis PCS (23).

αβ8 integrin as a player in the gene regulatory network driving PCO. Lens injury/cataract surgery results in the EMT of LCs to myofibroblasts that proliferate, migrate, contract the lens capsule, and produce a fibrotic matrix, which all contribute to the degradation of patient vision PCS (3). Most studies of this process start by considering the role of active TGF-β in this phenotypic conversion, though less attention has been paid to how cataract surgery initiates this process (8). Here we report that upregulation of αβ8 integrin levels on LCs PCS is an important step in their reprogramming into myofibroblasts and suggest that this reprogramming starts 1–2 days before upregulation of detectable canonical TGF-β signaling in these cells, as the upregulation of the mRNAs encoding numerous profibrotic proteins was attenuated in β1ITG-cKO LCs 24 hours PCS. As many of these genes have been previously reported to be TGF-β responsive in other cell types (Supplemental Tables 9 and 10), this observation supports our prior model, which proposed that a small upregulation in the protein levels of a TGF-β-activating integrin could lead to a feedforward loop that can rapidly induce autocrine TGF-β-mediated fibrosis (12).

Notably, the profibrotic modulators whose upregulation is attenuated in β1ITG-cKO 24 hours PCS included gremlin-1, a BMP signaling antagonist (35), and TGF-β signaling agonist (23, 28, 36), which usually upregulate sharply by 24 hours PCS. We previously found that LCs lacking the fibronectin gene exhibited greatly attenuated gremlin-1, p-SMAD2/3, and fibrotic marker upregulation PCS, while treatment of capsular bags with exogenous gremlin-1 rescued the ability of fibronectin-null LCs to undergo fibrotic responses (23). However, while both gremlin-1 expression and p-SMAD2/3 signaling are attenuated in β1ITG-cKO LCs, treatment of these cells with exogenous gremlin-1 did not rescue either p-SMAD2/3 signaling or the fibrotic response of β1ITG-cKO LCs, though exogenous treatment of these cells with active TGF-β1 rescued the fibrotic response. This suggests that gremlin-1 is not eliciting its response directly via the TGF-β receptor and instead may facilitate latent TGF-β activation by an as-yet-unknown mechanism. Alternatively, there could be differences in the requirements for gremlin-1 at different times PCS, with αβ8 integrin’s ability to activate TGF-β signaling at early times PCS kick-starting gremlin-1 expression so that it can influence TGF-β signaling later PCS (23). This concept is supported by work on other cell types suggesting that early activation of endogenous TGF-β is critical for gremlin-1 to exert its profibrotic response later in fibrotic disease (38, 39). Further study is required to elucidate the molecular mechanisms and therapeutic potential (if any) of gremlin-1 in PCO.

αβ8 integrin blockade in halting the onset and progression of fibrotic PCO. The emerging role of αβ8 integrin in TGF-β1 (and likely TGF-β3) activation has led to intense research into both antibody and small molecule inhibitors of αβ8 integrin–TGF-β interactions for the treatment (and monitoring) of fibrotic and neoplastic disease (15, 16, 34, 54). In most proof-of-principle experiments for this approach, these drugs prevent the onset of disease in animals, though this would not be clinically efficacious in most cases as fibrotic damage is often extensive by the time clinical symptoms manifest (40). However, treatment before the onset of fibrotic disease could be a viable option for anti-PCO therapy as the initiating insult (cataract surgery) is known, and the site of fibrosis is accessible during surgery, making local administration of the drug feasible. Here we validate this approach in an animal model of PCO as we found that the treatment of mice at the time of surgery with an anti-αβ8 integrin function blocking antibody prevented the development of the fibrotic sequelae of lens fiber cell removal and thus presumably fibrotic PCO. Our preclinical study supports the idea that this blocking antibody may be useful to halt fibrotic progression in patients who have already developed PCO. However, it should be mentioned that although the levels of p-SMAD3 activation and other fibrotic protein levels reversed in LCs to levels similar to the unoperated lens when mice were treated after fibrosis was established, α-SMA protein levels were still elevated, which may result from its relative stability as the half-life of α-SMA protein in cells is 72 hours (55).

Limitations of this study for clinical translation as a PCO preventative. While data presented here suggest that therapeutics blocking αβ8 integrin’s ability to activate TGF-β1 have great promise in preventing fibrotic PCO, unanswered questions remain. First, the function blocking antibody therapy used in this study was administered to the animals intravenously as the systemic administration of ADWA-11 showed no evidence of toxicity...
Homozygous 

This study established that α8 integrin is essential for LCs to transition to myofibroblasts following lens injury, likely through its ability to activate latent TGF-β1 and/or TGF-β3. Blocking α8 integrin binding to lenses via antibody blockade phenocopied the response of β8 integrin blockade to reverse fibrotic ECM deposition associated with mouse capsular bags at 5 days PCS, we expect this matrix to still be relatively immature at this time and thus relatively susceptible to turnover. Future work will be needed to determine whether anti-α8 integrin therapeutics can reverse fibrosis in more established fibrotic conditions where the scar tissue has developed abundant amounts of cross-linked collagen.

Summary. This study established that α8 integrin is essential for LCs to transition to myofibroblasts following lens injury, likely through its ability to activate latent TGF-β1 and/or TGF-β3. Blocking α8 integrin binding to lenses via antibody blockade phenocopied the response of β8 integrin blockade to reverse fibrotic ECM deposition associated with mouse capsular bags at 5 days PCS, we expect this matrix to still be relatively immature at this time and thus relatively susceptible to turnover. Future work will be needed to determine whether anti-α8 integrin therapeutics can reverse fibrosis in more established fibrotic conditions where the scar tissue has developed abundant amounts of cross-linked collagen.

Methods

Animals. All mice were maintained under pathogen-free conditions at the University of Delaware animal facility under a 14-hour light/10-hour dark cycle. Animals of both sexes were used in these experiments, and no sex-dependent effects were noted, consistent with our prior report (63).

Mice homozygous for a null mutation in the β8 integrin gene were originally obtained from The Jackson Laboratory (Itgb8tm2Lfr, mixed [C57BL/6J 129/Sv], from the University of California, San Francisco; UCSF) (49). Homozygous β8 integrin–null mice (Itgb8tm2Lfr) on a 129Svems genetic background were obtained from Xiaozhu Huang (UCSF) (50). Mice lacking β6 integrin subunit gene from the lens (β6ITG-cKO) were created by mating mice harboring an integrin β6 allele on a mixed C57BL/6J 129/Sv background in which exon 4 is flanked by loxP sites (Itgb6tm1m2; obtained from UCSF) (21) with MLR10-cre mice on a C57BL/6 background, which express Cre recombinase in all LCs from the lens vesicle stage onward (22) (obtained from Michael Robinson, Miami University, Oxford, Ohio, USA), backcrossed to C57BL/6<har> for over 10 generations.

Human eyes. Transparent lenses (30 ± 2 years of age) were obtained from Lions Eye Bank of Oregon (Portland, Oregon, USA), and aphakic donor eyes were obtained from the Minnesota Lions Eye Bank (Minneapolis, Minnesota, USA) as part of their cadaver eye tissue procurement programs. Intact lenses or lens capsular bag/IOL implant complexes were isolated, fresh frozen in OCT medium, and prepared for immunofluorescence experiments as described below.

Genotyping and PCR. DNA was isolated from tail snips or whole lenses using the PureGene Tissue and Mouse Tail kit (Gentra Systems) as described (13) and genotyped by PCR using primers described in Supplemental Table 1 (64, 65). The deletion of exon 4 of the integrin β6 gene from the lens was confirmed by PCR analysis of genomic DNA isolated from adult lenses using the primers described in Supplemental Table 1 (65).

Morphological analysis. Lens clarity was determined by viewing isolated lenses using darkfield optics while lens optical properties were assessed by placing lenses on a 200-mesh electron microscopy grid as described previously (66).

Mouse cataract surgery model. Surgical removal of lens fiber cells to mimic human cataract surgery was performed in adult mice as previously described (13, 67). Briefly, adult mice were anesthetized, a central corneal incision was made, and the entire lens fiber cell mass removed by a sharp forceps, leaving behind an intact lens capsule. Mice were sacrificed for analysis at time intervals ranging from 24 hours to 10 days PCS (13).
RNA-Seq and bioinformatics. Samples from WT (C57BL/6) and βITG-cKO lenses subjected to cataract surgery (3 biological replicates for each condition, 5 capsules per replicate) were harvested at 0 hours and 24 hours PCS and frozen on dry ice, and RNA was harvested using RNAeasy Mini Kit (50) from QIAGEN (catalog 74104) (23). RNA libraries were prepared using the SMARTer Stranded Total RNA-Seq Kit-Pico Input Mammalian (Takara Bio USA, Inc.) and sequenced by DNA Link, USA, on a NovaSeq 6000 (Illumina). Read pairs corresponding to RNA fragments were enumerated as FPKM by Cuffdiff. Biologically significant differentially expressed genes (DEGs) were defined as those exhibiting statistically significant changes (FDR ≤ 0.05), a change in mRNA level greater than 2 FPKM between conditions, fold change greater than 2 in either the positive or negative direction, and expression levels in either condition that were 2 FPKM or greater (8, 23, 25). Heatmaps were generated using the Morpheus tool (68). RNA-Seq data were submitted to the National Center for Biotechnology Information's Gene Expression Omnibus under accession number GSE145492.

A list of 1603 TGF-β-responsive genes in cultured cells (32) was filtered to consider only those statistically significant (FDR ≤ 0.05) genes with consistent directions of change between treatments, leaving 1390 genes as likely to be directly TGF-β responsive. This filtered list was then compared with the list of genes differentially expressed in WT LCs between 0 and 24 hours PCS and between WT and βITG-cKO LCs 24 hours PCS (FDR ≤ 0.05) to discover what proportion of the DEG list had the potential to be influenced by TGF-β signaling the first day PCS.

Phenotypic rescue by active TGF-β1 and gremlin-1. Rescue experiments were performed by instilling active recombinant human TGF-β1 protein (5 μL of 0.1 ng/μL TGF-β1 in balanced saline solution; BSS; R&D Systems; catalog 240-B) or recombinant human gremlin-1 protein (5 μL of 1 ng/μL gremlin-1 in BSS; R&D Systems, catalog 5190-GR) or the BSS vehicle alone into the lens capsular bags of βITG-cKO mice immediately following removal of the lens fibers as previously described (23).

Tail vein injection of α,β, α,β, and α,β integrin function blocking antibodies. Tail vein injection of α,β, α,β, and α,β integrin function blocking antibodies was performed as described (69). Briefly, a single dose of ALULA (α,β, integrin blocking) (70), 3G9 (α,β, integrin blocking) (71), or ADWA-11 (α,β, integrin blocking) (34) was administered to WT mice at 20 mg/kg in PBS via lateral tail vein injection immediately following removal of the lens fiber cells from 1 eye. In another experiment, either a single dose of ADWA-11 (at 5 days PCS) or 2 doses of ADWA-11 (at 5 days PCS and 7.5 days PCS) was administered to WT mice. Control animals were treated with an isotype-matched antibody (anti–human α,β, integrin that does not cross-react with the mouse α,β, integrin protein) at 20 mg/kg in PBS. All the integrin function blocking antibodies were obtained from UCSF.

Immunofluorescence. The details of sample preparation and immunofluorescence were described previously (23, 72). Supplemental Table 2 describes the primary antibodies, blocking buffer compositions, incubation times, and dilutions used in this study, and Supplemental Table 3 lists the secondary antibodies and DNA dyes used in this study. Each experiment/time point was replicated using at least 3 biologically independent specimens (3–5 mice, at least 2 sections per mouse). Fluorescently labeled slides were visualized using Zeiss LSM780 or Zeiss LSM880 confocal microscopes (Carl Zeiss Inc.), and comparisons of images were made between slides imaged using identical imaging parameters (73). In some cases, the brightness and contrast were adjusted to allow viewing on diverse computer screens; however, these adjustments were made identically for all images within a particular time course. Negative controls were prepared and imaged to exclude nonspecific staining by the secondary antibodies or channel bleed-through as previously described (23, 72, 73).

ImageJ (NIH) quantification and statistics. Immunofluorescence images were quantified by determining the MFI of lens capsule–associated tissue viewed in 3 randomly chosen confocal images from biologically independent samples using ImageJ (v1.52P, NIH) (73). The average number of lens capsule–associated nuclei/section was analyzed by ImageJ using 6 randomly chosen immunofluorescence images from each PCS time point from at least 3 biologically independent samples as described (73, 74).

The diameter of adult lenses was determined by dissecting both lenses from 3 WT and 3 βITG-cKO mice and photographing them in brightfield using a Zeiss STEMI SV 11 dissecting microscope. The diameter of each lens was measured in 2 perpendicular axes using ImageJ, then averaged for statistical analysis.

All statistics were assessed using either 2-tailed Student’s t test (corrected for multiple comparisons using the Holm-Šidák method) or 1-way/2-way ANOVA with Tukey’s post hoc test using GraphPad Prism 8.3.0/9.2.0. Data are presented as mean ± SEM, and differences were considered significant at P ≤ 0.05.

Study approval. Animal experiments conformed to the Association for Research in Vision and Ophthalmology Statement on the Use of Animals in Ophthalmic and Vision Research and were approved.
by the University of Delaware Institutional Animal Care and Use Committee. Experiments using human cadaver-derived lens tissue were reviewed by the University of Delaware Institutional Review Board and were judged as exempt from review.

**Author contributions**

MHS designed research studies, conducted experiments, analyzed data, and wrote the manuscript; SGN conducted experiments and analyzed data; YW designed research studies and conducted experiments; DS provided reagents and designed studies; AA provided reagents and designed studies; TDA provided reagents and designed studies; NMR conducted experiments; APF analyzed data and designed studies; and MKD designed research studies, analyzed data, and wrote the manuscript.

**Acknowledgments**

This study was supported by NIH grant EY015279 to MKD, NMR’s research fellowships from the University of Delaware Undergraduate Research program, Delaware INBRE (P20 GM103446), the State of Delaware–supported University of Delaware Center for Bioimaging, and 1S10 (RR027273-01), which funded the acquisition of the confocal microscope used in this study.

Address correspondence to: Melinda K. Duncan, Department of Biological Sciences, Newark, Delaware 19716, USA. Phone: 302.831.0533; Email: duncanm@udel.edu.

---


